Found 27 cancer-center trials
A listing of cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Double-blind, randomized, single-center pilot study to assess the effectiveness of pregabalin (Lyrica) in the management of mucositis pain in head and neck cancer.
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
Our study is a Phase 1Ib/2 clinical trial to evaluate the safety and feasibility of the combination of radiotherapy (RT) in a single fraction of 7 Gy with pembrolizumab in patients with operable breast cancer. We will employ a Simon Two Stage design to evaluate the safety, feasibility, and efficacy …
